Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA multi-valent influenza vaccine
- Development stage
- Preclinical
- Lead developer
- CanSino Biologics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The mRNA multi-valent influenza vaccine is a preclinical-stage prophylactic vaccine candidate developed by CanSino Biologics (through its subsidiary Cansino (Beijing) Biotechnology). Utilizing a messenger RNA (mRNA) platform, the vaccine is designed to encode antigens from multiple influenza virus strains, specifically targeting the hemagglutinin (HA) and neuraminidase (NA) proteins. By delivering mRNA that instructs host cells to produce these viral proteins, the vaccine aims to elicit a broad and potent immune response, including both neutralizing antibodies and T-cell activity, to protect against seasonal or pandemic influenza. The mRNA approach offers advantages in manufacturing speed and flexibility compared to traditional egg-based production methods, potentially allowing for a better antigenic match to circulating strains.
- Other names
- mRNA Multi-valent Influenza Vaccine
02
Targets
Innate immune RNA-sensing receptorsNeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA multi-valent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA multi-valent influenza vaccine.